food noise back on tirzepatide Only went up to 3.5 and is back, should I go up again? : r/compoundedtirzepatide Tirzepatide may only temporarily suppress

Pharmacokinetics In recent years, a various studies have investigated the pharmacokinetics of semaglutide, including pharmacokinetics in healthy individuals, pharmacokinetics in patients with various diseases, and the effects of drugdrug interactions and drugfood interactions on the pharmacokinetics of semaglutide in humans

PCT/EP2018/072835 2017-08-24 2018-08-24 Glp-1 compositions and uses thereof Ceased WO2019038412A1 (en) Priority Applications (28) Applications Claiming Priority (2) Related Child Applications (1) Publications (1) Family ID=59713860 Family Applications (1) Country Status (25) Cited By (12) Families Citing this family (12) Citations (2) Family Cites Families (469) 2018 2018-08-24 KR KR1020207006965A patent/KR102665710B1/en active Active 2018-08-24 MX MX2020001525A patent/MX2020001525A/en unknown 2018-08-24 TW TW111139129A patent/TWI847306B/en active 2018-08-24 TW TW111110149A patent/TWI783890B/en active 2018-08-24 MA MA46990A patent/MA46990B1/en unknown 2018-08-24 PH PH1/2020/550051A patent/PH12020550051B1/en unknown 2018-08-24 AU AU2018321157A patent/AU2018321157B2/en active Active 2018-08-24 CA CA3082033A patent/CA3082033A1/en active Pending 2018-08-24 HR HRP20240485TT patent/HRP20240485T1/en unknown 2018-08-24 WO PCT/EP2018/072835 patent/WO2019038412A1/en not_active Ceased 2018-08-24 CN CN202411246465.5A patent/CN118903385A/en active Pending 2018-08-24 CN CN201880054209.2A patent/CN111050750B/en active Active 2018-08-24 JP JP2018561585A patent/JP6633777B2/en active Active 2018-08-24 RS RS20240414A patent/RS65380B1/en unknown 2018-08-24 TW TW107129632A patent/TWI762706B/en active 2018-08-24 AR ARP180102424 patent/AR112480A1/en not_active Application Discontinuation 2018-08-24 BR BR112020002804-5A patent/BR112020002804A2/en unknown 2018-08-24 EP EP18756449.7A patent/EP3474820B1/en active Active 2018-08-24 EP EP24155461.7A patent/EP4360651A3/en active Pending 2018-08-24 CN CN202411246627.5A patent/CN118903386A/en active Pending 2018-08-24 PL PL18756449.7T patent/PL3474820T3/en unknown 2018-08-24 SG SG11202000940XA patent/SG11202000940XA/en unknown 2018-08-24 ES ES18756449T patent/ES2976496T3/en active Active 2018-08-24 HU HUE18756449A patent/HUE066356T2/en unknown 2018-08-24 PE PE2020000202A patent/PE20211202A1/en unknown 2018-08-24 MY MYPI2020000624A patent/MY198425A/en unknown 2020 2020-01-24 IL IL272232A patent/IL272232B1/en unknown 2020-01-28 US US16/774,666 patent/US10888605B2/en active Active 2020-02-20 CL CL2020000422A patent/CL2020000422A1/en unknown 2020-03-09 CO CONC2020/0002647A patent/CO2020002647A2/en unknown 2020-12-08 US US17/115,773 patent/US11752198B2/en active Active 2021 2021-05-31 CL CL2021001430A patent/CL2021001430A1/en unknown 2023 2023-07-26 US US18/226,405 patent/US20240016896A1/en active Pending 2024 2024-01-30 US US18/427,270 patent/US12214017B2/en active Active 2024-06-18 AU AU2024204151A patent/AU2024204151B2/en active Active Patent Citations (2) Non-Patent Citations (3) Cited By (26) Also Published As Similar Documents Legal Events

The guidance further notes that criteria for selecting P-gp clinical substrates are (a) AUC fold-increase 2 with verapamil or quinidine co-administration and (b) in vitro transport by P-gp expression systems, but not extensively metabolized

Hjrup, E.I